<a href="https://www.fiercebiotech.com/biotech/regeneron-pays-37m-adds-2b-biobucks-expand-cytomx-pact" hreflang="en">Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact</a>
Regeneron Pharmaceuticals has expanded its research collaboration with CytomX Therapeutics, investing $37 million and increasing the potential value of the partnership to approximately $4 billion, focusing on developing conditionally active bispecific antibodies for cancer treatment. This expansion comes amidst recent terminations of collaborations between CytomX and other companies, highlighting the challenges faced by the biotech firm.
Regeneron's expanded partnership with CytomX Therapeutics, now valued at up to $4 billion, highlights the significant investment and confidence in CytomX's technology for conditionally active bispecific antibodies targeting cancer. This deal reinforces the strategic importance of technologies that can minimize off-target effects and expand therapeutic windows, making them attractive for future collaborations and investments, despite recent setbacks with other major partners.